EcoDrugPlus

26s Proteasome Regulatory Subunit 7

Ensembl ID : ENSSSAG00000095722
Gene Symbol: LOC106609683
4 Cross references
230 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSSSAG00000049070
Gene Symbol: HMGCR
2 Cross references
195 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase

Ensembl ID : ENSSSAG00000077677
Gene Symbol: HMDH
4 Cross references
205 Possible Orthologues:

3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2

Ensembl ID : ENSSSAG00000051978
Gene Symbol: LOC106564819
4 Cross references
202 Possible Orthologues:

3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2

Ensembl ID : ENSSSAG00000044549
Gene Symbol: S5A2
4 Cross references
202 Possible Orthologues:

3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2-Like

Ensembl ID : ENSSSAG00000040957
Gene Symbol: LOC106590888
4 Cross references
191 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1b

Ensembl ID : ENSSSAG00000054521
Gene Symbol: PDPK1B
3 Cross references
214 Possible Orthologues:

3-Phosphoinositide-Dependent Protein Kinase 1-Like

Ensembl ID : ENSSSAG00000042015
Gene Symbol: LOC106578264
4 Cross references
215 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSSSAG00000081678
Gene Symbol: LOC106585509
4 Cross references
198 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase-Like

Ensembl ID : ENSSSAG00000006836
Gene Symbol: LOC106579929
4 Cross references
198 Possible Orthologues:

40s Ribosomal Protein S15

Ensembl ID : ENSSSAG00000119924
Gene Symbol: RS15
4 Cross references
288 Possible Orthologues:

40s Ribosomal Protein S19

Ensembl ID : ENSSSAG00000003049
Gene Symbol: LOC106605681
4 Cross references
300 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).